Join
Live feed
·
PRReleasevia Quantisnow
Caribou Biosciences Inc. logo

Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress

ByQuantisnow·Wall Street's wire, on your screen.
CRBU· Caribou Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRBU (Caribou Biosciences Inc.) and more on Quantisnow.